Intrafamilial and Age-Dependent Variability in Resistance to Thyroid Hormone Alpha: A Case Report Authors: Elise Nauwynck, Sofie Ryckx, Daniel Klink, Sietske Vermaning, Marije Meuwissen, Lisa Billion, Jean De Schepper Published: 2026 ABSTRACT AbstractIntroductionResistance to thyroid hormone alpha (RTHα) is a rare genetic disorder caused by pathogenic variants in the thyroid hormone receptor alpha (THRA) gene, characterized by tissue-specific hypothyroidism despite often normal circulating thyroid hormone levels.Case PresentationIn this report, we describe a family of three individuals – two sisters and their mother – carrying a heterozygous missense variant (c.1207G>A) in THRA. The variant was identified after evaluation of the daughters for short stature, increasing adiposity, and delayed bone age. Hormonal assessments revealed subtle thyroid function abnormalities, including low-normal free thyroxine (FT4), high-normal free tri-iodothyronine (FT3), an elevated FT3/FT4 ratio, and normal thyroid-stimulating hormone (TSH) levels. Additional clinical features included variably present delayed dentition, chronic constipation, and hepatic steatosis. Both sisters exhibited normocytic anemia and delayed language development.ConclusionThis report adds novel insight by documenting intrafamilial variability and age-related attenuation of biochemical abnormalities in a family carrying a previously described THRA variant. It emphasizes the risk of missed diagnosis when relying solely on thyroid function tests and illustrates the importance of family-based evaluation across the lifespan, including in adults who may present with subtler biochemical or metabolic abnormalities. RTHα should be considered in patients with growth delay, disproportionate weight gain, persistent normocytic anemia, or developmental delay, even when thyroid hormone levels appear near-normal. Awareness of these patterns can prevent delayed diagnosis and support individualized clinical management. Established Facts RTHα is a rare dominantly inherited disorder caused by heterozygous pathogenic variants in the THRA gene, resulting in impaired thyroid hormone receptor α (TRα1) function.Hypothyroid symptoms occur in tissues predominantly expressing TRa as tissues expressing both TRa and TRb are generally not in a clinically hypothyroid state, with routine thyroid tests often normal and a typical biochemical feature being an elevated FT3/FT4 ratio.The condition is frequently underdiagnosed due to its phenotypic variability. Novel Insights This report demonstrates marked clinical heterogeneity among carriers of the same THRA missense variant (c.1207G >A), highlighting that disease severity in RTHα cannot be reliably predicted by genotype alone.Attenuation of characteristic biochemical abnormalities (e.g., anemia, elevated SHBG/copper, elevated CK) in adulthood underscores the risk of missed diagnosis when relying solely on thyroid function tests and supports the value of family-based evaluation. Established Facts RTHα is a rare dominantly inherited disorder caused by heterozygous pathogenic variants in the THRA gene, resulting in impaired thyroid hormone receptor α (TRα1) function.Hypothyroid symptoms occur in tissues predominantly expressing TRa as tissues expressing both TRa and TRb are generally not in a clinically hypothyroid state, with routine thyroid tests often normal and a typical biochemical feature being an elevated FT3/FT4 ratio.The condition is frequently underdiagnosed due to its phenotypic variability. RTHα is a rare dominantly inherited disorder caused by heterozygous pathogenic variants in the THRA gene, resulting in impaired thyroid hormone receptor α (TRα1) function. RTHα is a rare dominantly inherited disorder caused by heterozygous pathogenic variants in the THRA gene, resulting in impaired thyroid hormone receptor α (TRα1) function. Hypothyroid symptoms occur in tissues predominantly expressing TRa as tissues expressing both TRa and TRb are generally not in a clinically hypothyroid state, with routine thyroid tests often normal and a typical biochemical feature being an elevated FT3/FT4 ratio. Hypothyroid symptoms occur in tissues predominantly expressing TRa as tissues expressing both TRa and TRb are generally not in a clinically hypothyroid state, with routine thyroid tests often normal and a typical biochemical feature being an elevated FT3/FT4 ratio. The condition is frequently underdiagnosed due to its phenotypic variability. The condition is frequently underdiagnosed due to its phenotypic variability. Novel Insights This report demonstrates marked clinical heterogeneity among carriers of the same THRA missense variant (c.1207G >A), highlighting that disease severity in RTHα cannot be reliably predicted by genotype alone.Attenuation of characteristic biochemical abnormalities (e.g., anemia, elevated SHBG/copper, elevated CK) in adulthood underscores the risk of missed diagnosis when relying solely on thyroid function tests and supports the value of family-based evaluation. This report demonstrates marked clinical heterogeneity among carriers of the same THRA missense variant (c.1207G >A), highlighting that disease severity in RTHα cannot be reliably predicted by genotype alone. This report demonstrates marked clinical heterogeneity among carriers of the same THRA missense variant (c.1207G >A), highlighting that disease severity in RTHα cannot be reliably predicted by genotype alone. Attenuation of characteristic biochemical abnormalities (e.g., anemia, elevated SHBG/copper, elevated CK) in adulthood underscores the risk of missed diagnosis when relying solely on thyroid function tests and supports the value of family-based evaluation. Attenuation of characteristic biochemical abnormalities (e.g., anemia, elevated SHBG/copper, elevated CK) in adulthood underscores the risk of missed diagnosis when relying solely on thyroid function tests and supports the value of family-based evaluation. Introduction Resistance to thyroid hormone alpha (RTHα), also referred to as congenital non-goitrous hypothyroidism (OMIM 614450), is a rare genetic disorder caused by heterozygous pathogenic variants in the THRA gene on chromosome 17 [1–3]. These variants impair the function of thyroid hormone receptor alpha (TRα), resulting in tissue-specific hypothyroid features despite near-normal circulating thyroid hormone concentrations. Through alternative splicing, THRA encodes two isoforms: TRα1, the biologically active receptor expressed predominantly in the central nervous system, myocardium, gastrointestinal tract, and skeletal muscle, and TRα2, a non-thyroid hormone-binding isoform with preserved DNA interaction. Most reported pathogenic variants reduce TRα1-mediated signaling to varying degrees, accounting for the broad phenotypic spectrum observed in affected individuals [2]. Clinically, RTHα is characterized by features of hypothyroidism in TRα1-expressing tissues, including neurodevelopmental delay, growth impairment, constipation, and bradycardia. However, standard thyroid function tests are often nondiagnostic, typically showing low-normal free thyroxine (FT4), high-normal free tri-iodothyronine (FT3), and normal thyroid-stimulating hormone (TSH), sometimes accompanied by reduced reverse T3 (rT3). Because these findings frequently fall within laboratory reference ranges, diagnosis may be overlooked when relying solely on conventional biochemical screening. The estimated prevalence of RTHα is approximately 1 in 40,000, but true prevalence is likely higher due to underrecognition [1, 3]. The heterozygous missense variant c.1207G>A in THRA has been previously reported. However, detailed descriptions of intrafamilial variability across different life stages remain limited. In this report, we describe three affected members from one family carrying this variant, demonstrating marked phenotypic variability from childhood to adulthood, discordant biochemical profiles, and differences in clinical severity. By illustrating how the diagnosis might have been missed in the absence of systematic family evaluation and genetic testing, this case series underscores the limitations of relying exclusively on thyroid function tests and highlights the importance of cascade screening and longitudinal assessment in families with suspected RTHα. Case Presentation Two sisters, aged 2.5 and 5 years, were referred for evaluation due to short stature and excessive weight gain. The younger sister was born at 38 weeks and 5 days of gestation, with a birth weight of −1.4 standard deviation score (SDS), birth length of −1.2 SDS, and head circumference (HC) of −0.7 SDS. Postnatally, she exhibited limited catch-up growth but experienced a significant increase in body mass index (BMI) after 6 months of age. Clinical features included delayed tooth eruption, generalized hypotonia, and delayed motor and language development. Genetic testing for Prader-Willi syndrome, myotonic dystrophy type 1 (Steinert disease), and spinal muscular atrophy yielded normal results. The older sister was born at term (40 weeks gestation) with birth parameters within normal ranges. Between 6 and 20 months of age, she experienced faltering linear growth despite normal weight gain, resulting in an elevated BMI. She also exhibited chronic constipation and delayed language development characterized by dysarthric speech. The mother reported a history of learning difficulties and dysarthric speech but did not exhibit hypotonia. Childhood growth data were not available, and she had not received any thyroid hormone treatment during childhood, ruling out exogenous therapy as a contributor to her phenotype. In adulthood, she developed atrioventricular nodal reentrant tachycardia, insulin resistance, and hepatic steatosis. Her current height was 158 cm (−1.4 SDS), and her BMI was 43.2 kg/m2. The father was healthy, with a height of 179 cm (−0.1 SDS) and BMI of 22 kg/m2. On clinical examination, both girls presented with short stature (−3.8 SDS and −2.5 SDS), elevated BMI (+1.5 SDS and +1.3 SDS), and relative macrocephaly (HC +0.2 SDS and +0.9 SDS). Global hypotonia was noted in both, while the older sister also exhibited facial dysmorphic features, including a round face, full cheeks, and an upturned nose. Bone age was delayed by 14 months in the younger sister and by 9 months in the older. Biochemical testing revealed normocytic anemia in both girls, with normal erythrocyte sedimentation rate, serum lipid profile, and liver function tests. Hormonal evaluation showed normal serum insulin-like growth factor 1 (IGF-1) levels in both. The younger sister had low FT4 and elevated FT3, while both had an elevated FT3/FT4 ratio. Sex hormone-binding globulin (SHBG) levels were borderline high, despite their increased BMI (Table 1). Table 1.Biometric, biochemical, and radiographic features of RTHα patients​MotherSister 1Sister 2Age, years3852.5Skeletal Height, cm158 (−1.4 SDS)102.5 (−2.5 SDS)78.5 (−3.8 SDS) BMI, kg/m242.3 (+2.7 SDS)17.61 (+1.3 SDS)18.01 (+1.5 SDS) Head circumference, cmUnknown52 (+0.9 SDS)49 (+0.2 SDS) Bone age (Greulich and Pyle, BonXpert), years, monthsUnknown4 yr 2 mo, 4 yr 2 mo1 yr 6 mo, 1 yr 2 mo Delayed dentitionUnknownNoYesAppearance MacroglossiaUnknownNoNo Broad faciesUnknownYesYes Flat nasal bridgeUnknownYesYesGastrointestinal ConstipationNoYesNo Hepatic steatosisYesNoNoNeurocognitive Delayed milestonesYesYesYes Motor dyspraxiaNoNoYes DysarthriaYesYesNo Cognitive functionLearning problemsNANABiochemical TSH, mIU/L1.28 (0.27–4.2)4.25 (0.7–5.97) 6.29 (0.7–5.97) FT4, pmol/L14.0 (11.9–21.6)12.8 (12.3–22.8) 12.2 (12.3–22.8) FT3, pmol/L6.52 (3.1–6.8)8.4 (3.7–8.5) 9.4 (3.7–8.5) FT3/FT4 ratio 0.47 (0.28–0.36) 0.66 (0.3–0.53) 0.77 (0.32–0.54) CK, U/LUnknown 197 (<149)148 (<228) IGF1, µg/LUnknown77.5 (19.0–251.0)59.0 (11.0–165.0) MCV, fLUnknown86 (77.4–92.1)83.2 (77.4–92.1) Hb, g/dLUnknown 10.2 (11.2–14.1) 9.5 (11.2–14.1) SHBG, nmol/LUnknown130 (47.8–142.1)135 (51.4–157.7) Total cholesterol, mg/dLUnknown179 (<190) 192 (<190) Copper, µg/dLUnknown149 (90–190) 212 (90–190)The bold values are the values outside the reference range. Biometric, biochemical, and radiographic features of RTHα patients The bold values are the values outside the reference range. Given the limited specificity of clinical and biochemical findings to guide targeted genetic testing, whole-exome sequencing was undertaken and identified a maternally inherited heterozygous pathogenic missense variant in the THRA gene (c.1207G>A) in both girls. Further laboratory investigations showed normal serum creatine kinase (CK) and lactate dehydrogenase in both. The younger sister additionally exhibited elevated serum ceruloplasmin and copper levels. Cardiological evaluation, including blood pressure, electrocardiogram, and echocardiography, was unremarkable in both children. This case report was prepared in accordance with the CARE guidelines. The CARE checklist is provided as online supplementary material (for all online suppl. material, see https://doi.org/10.1159/000552527). Discussion Thyroid hormone receptor alpha mutations lead to RTHα, a rare and often underrecognized condition marked by tissue-specific thyroid hormone insensitivity. The phenotypic spectrum of RTHα is notably heterogeneous, ranging from mild developmental delays to more pronounced neurologic and growth abnormalities, which frequently complicates timely diagnosis. In this report, we describe a family harboring a shared pathogenic THRA missense variant that demonstrates marked intrafamilial variability in clinical presentation, underscoring the challenges in diagnosis and the importance of considering RTHα in the differential diagnosis of pediatric patients presenting with short stature, increasing adiposity, and developmental delay with slightly disturbed or normal thyroid levels. Clinically, patients harboring THRA mutations exhibit a spectrum of hypothyroid manifestations in tissues expressing the TRα1 receptor. Neurologically, this includes global developmental delay, motor dyspraxia, dysarthric speech, ataxic gait, and variable intellectual impairment. Skeletal abnormalities commonly observed comprise faltering growth, relative macrocephaly, delayed dentition, and distinctive dysmorphic features such as a broad face, hypertelorism, flattened nasal bridge, macroglossia, and thickened lips. Muscular involvement is characterized by decreased resting energy expenditure, contributing to increased BMI. Cardiac manifestations reflect central autonomic dysfunction, including abnormal sympathovagal balance resulting in hypotension and bradycardia, while gastrointestinal symptoms primarily involve delayed motility causing severe constipation [1, 2, 4, 5]. Radiographically, affected children frequently show delayed fontanelle closure, delayed bone age, markedly serpiginous cranial sutures, and femoral epiphyseal dysgenesis. In adulthood, thickening of the calvarium, cortical hyperostosis of long bones, and increased bone mineral density are common findings [1]. Familial cases sharing identical pathogenic THRA variants often display a consistent phenotype characterized by short stature, overweight, macrocephaly, and delayed language development [4, 6, 7]. In the present family, both sisters exhibited short stature, a high-normal BMI, relative macrocephaly, delayed neurological milestones, and delayed bone maturation. However, only 1 sibling presented with additional features of hypothyroidism, including delayed dentition, constipation, and motor dyspraxia. While bradycardia is a more typical cardiac feature in RTHα, the mother’s atrioventricular nodal reentrant tachycardia likely represents a coincidental arrhythmia rather than a direct consequence of TRα dysfunction. Hepatic steatosis was uniquely observed in the mother. Notably, increased central adiposity and hepatic steatosis have been described in murine models of RTHα, attributed to diminished catecholaminergic response and a metabolic shift toward energy-conserving anabolic activity, similar to human cases of resistance to thyroid hormone beta (RTHβ), where impaired β-oxidation of free fatty acids plays a pivotal role [8–11]. One of the primary reasons THRA mutations remain clinically underrecognized is the subtle alteration of the thyroid hormone profile. In RTHα, hypothalamic-pituitary-thyroid axis signaling is largely preserved due to intact TRβ2 function in the hypothalamus and pituitary. At the same time, elevated hepatic expression of type 1 deiodinase (D1) increases the conversion of T4 to T3, resulting in low-normal FT4 and high-normal FT3 levels. Additionally, decreased tissue levels of type 3 deiodinase, responsible for FT3 catabolism, contribute to reduced rT3 levels [5]. Because the pituitary senses primarily T3 via TRβ2, TSH secretion remains within the normal range, masking tissue-specific hypothyroidism in TRα-expressing organs [12]. However, several biochemical markers can raise suspicion for RTHα due to THRA mutations. Notably, an elevated FT3/FT4 ratio is a consistent finding in patients with RTHα and may serve as a suggestive biochemical indicator [4, 6, 7]. While a low FT4/FT3 ratio can help identify potential cases, it is not entirely specific and can also be observed in other disorders, such as dyshormonogenetic hypothyroidism or Allan-Herndon-Dudley syndrome due to MCT8 gene defects [1]. In RTHα, the altered FT3/FT4 ratio likely reflects changes in thyroid hormone metabolism. Increased hepatic type 1 deiodinase (DIO1) may enhance the conversion of FT4 to FT3 [13], while reduced tissue expression of type 3 deiodinase (DIO3), which is TRα1 regulated, could contribute by decreasing inner-ring deiodination of FT4 to reverse T3 and T3 to T2 [14]. Reference ranges for the FT3/FT4 ratio in children remain poorly defined as most pediatric studies report only individual FT3 and FT4 centiles, making ratio calculations impractical [15, 16]. Available data suggest that the FT3/FT4 ratio in healthy children is relatively stable, with mean values around 0.030–0.032 and minor age- or sex-related variations [17, 18]. Age- and sex-specific percentiles may therefore be important when interpreting subtle deviations in suspected RTHα, particularly during puberty, when transient fluctuations in thyroid hormone levels can occur. Moreover, mild normocytic anemia characterized by low hematocrit with normal serum iron, vitamin B12, folate levels, and unremarkable hemolytic indices (reticulocyte count, circulating haptoglobin, and lactate dehydrogenase) is a common finding. The anemia results from a partially impaired erythropoiesis as demonstrated in TRα-null mouse models [1, 19]. Furthermore, THRA gene mutations can induce elevated serum SHBG and ceruloplasmin levels, attributed to enhanced hepatic synthesis, since they are regulated by thyroid receptor beta in both humans and mice [1, 20]. Additional nonspecific laboratory abnormalities may include increased CK, elevated total and LDL cholesterol, and low-normal IGF-1 concentrations [1, 2]. In our family, both sisters exhibited anemia and high-normal SHBG, while one had elevated copper and the other increased CK, illustrating intrafamilial heterogeneity. The older sister’s laboratory abnormalities were generally less pronounced than those of the younger sister, except for CK, which remained elevated. Laboratory data from the mother were limited to FT4, FT3, TSH, and the FT3/FT4 ratio, precluding assessment of other biochemical markers; however, her thyroid hormone profile suggests attenuation of the characteristic abnormalities with age (Table 1). Collectively, these findings highlight that while supportive, biochemical markers in RTHα are neither uniform nor pathognomonic, emphasizing the need for careful clinical evaluation and family-based genetic testing. Affected individuals are heterozygous for pathogenic variants in the THRA gene. To date, approximately twenty-five distinct mutations have been reported, most of which result in loss of function due to frameshift mutations or premature stop codons. Patients carrying these mutations typically present with a more severe phenotype, frequently including intellectual disability [1, 2, 21]. In contrast, four missense mutations described in the literature lead to variable degrees of impaired function of the TRα1 protein [1, 2]. Elevated FT3 levels can partially mitigate the functional impairment of these mutant receptors by facilitating residual interaction with transcriptional corepressors in the presence of TH, resulting in a comparatively milder clinical phenotype [12, 22, 23]. Neurologically, affected individuals with missense mutations still exhibit reduced IQ scores, although these generally remain within the normal range [12]. Most pathogenic variants cluster within the divergent C-terminal domain encoded by the last exon, consistent with a dominant-negative mechanism by which the mutant TRα1 protein constitutively binds corepressors, resulting in impaired normal receptor function [12]. The missense variant identified in this Belgian family (c.1207G>A) is also located in the last exon of THRA isoform 1 and does not affect TRα2. This variant has been described previously in a Polish family and was associated with a relatively mild clinical phenotype [12]. Currently, there is no standardized therapy for RTHα, and treatment remains individualized and experimental. Levothyroxine has been the most commonly attempted agent, with reports suggesting improvement in general well-being, motor coordination, school performance, and constipation, particularly when initiated early to optimize neurocognitive outcomes [7, 21]. However, effects on anthropometric measures (height, BMI, head circumference) and cardiac function are generally limited [7, 21]. Evidence from Moran et al. indicates that the response may also depend on the specific THRA variant, with FT3-dependent reversibility of receptor dysfunction influencing clinical outcomes [2]. Following thyroxine treatment, TSH levels often suppress readily, with FT3 rising to supraphysiologic concentrations. In some patients, serum SHBG may increase further from high-normal baseline values [5], and markers of bone turnover can progressively rise. These patterns suggest that chronic exposure to excess thyroid hormone in RTHα may have unwanted effects on TRβ-expressing tissues, highlighting the importance of careful monitoring of cardiovascular, skeletal, and metabolic parameters during therapy. Given the variability in response, clinical and laboratory improvements should be evaluated separately for each patient, and higher-than-conventional doses have been considered in select cases [21]. In our family, a trial of high-dose thyroid hormone has been proposed under these individualized and closely monitored conditions. Future therapies may include TRα1-selective thyromimetics, which could selectively activate residual normal or partially defective TRα1 to overcome tissue-specific resistance while minimizing exposure to TRβ-containing tissues [24]. Overall, while no formal guidelines exist, early intervention remains the most evidence-supported strategy for supporting neurodevelopment, and treatment decisions must be tailored to the patient’s phenotype, genotype, and risk-benefit profile. Conclusion This report highlights pronounced intrafamilial phenotypic variability among carriers of the same THRA missense variant (c.1207G>A), demonstrating that clinical severity and biochemical expression in RTHα cannot be predicted by genotype alone. Although this variant has been previously described, our findings extend existing knowledge by documenting its heterogeneous presentation across different life stages within a single family, including attenuation of biochemical abnormalities in adulthood. In children presenting with short stature, delayed bone age, progressive adiposity, and language delay, the coexistence of elevated or high-normal SHBG levels and persistent normocytic anemia should prompt consideration of RTHα, even in the presence of apparently normal thyroid function tests. Our observations underscore that reliance on conventional thyroid biochemistry alone carries a substantial risk of missed or delayed diagnosis, particularly in mildly affected or older individuals. By demonstrating variable clinical expression and evolving biochemical profiles within 1 pedigree, this report emphasizes the critical importance of family-based genetic evaluation and cascade screening across the lifespan. Systematic assessment of relatives can uncover previously unrecognized cases and prevent underdiagnosis of RTHα, thereby refining clinical management and long-term follow-up strategies. Statement of Ethics The local Institutional Review Board deemed the study exempt from review. Written informed consent was obtained from the legal guardian and the patient. Conflict of Interest Statement The authors state there is no conflict of interest. Funding Sources The authors received no specific funding for this work. W.S. holds a senior clinical investigator grant from the Research Foundation Flanders (File No.: 1806426N). Author Contributions E.N. and J.D.S. wrote the original draft. S.R., D.K., S.V., M.M., and L.B. supervised the writing. J.D.S., S.V., and L.B. treated the patients. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.